Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free CGEM Stock Alerts

Cullinan Therapeutics (CGEM) Short Interest Ratio & Short Volume

Cullinan Therapeutics logo
$20.59 +0.25 (+1.23%)
As of 04:00 PM Eastern
Compare

Cullinan Therapeutics Short Interest Overview

As of July 31, 2026, Cullinan Therapeutics (CGEM) had a short interest of 10.25 million shares sold short, representing 17.43% of the public float. This marks a -0.31% decrease in short interest since the prior report. The short interest ratio (days to cover) is 19.2, meaning it would take 19.2 days of the average trading volume of 876,491 shares to cover all short positions.

Current Short Interest
10,254,541 shares
Previous Short Interest
10,285,963 shares
Change Vs. Previous Month
-0.31%
Dollar Volume Sold Short
$169.20 million
Short Interest Ratio
19.2 Days to Cover
Last Record Date
July 31, 2026
Outstanding Shares
64,360,000 shares
Short Percent of Float
17.43%
Today's Trading Volume
894,681 shares
Average Trading Volume
876,491 shares
Today's Volume Vs. Average
102%
Short Selling Cullinan Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Cullinan Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CGEM Short Interest Over Time

CGEM Days to Cover Over Time

CGEM Percentage of Float Shorted Over Time

Cullinan Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/31/202610,254,541 shares $169.20 million -0.3%17.4%19.17 $16.50
7/15/202610,285,963 shares $183.40 million -2.9%18.3%15.22 $17.83
6/30/202610,597,500 shares $192.98 million +29.5%18.9%6.62 $18.21
6/15/20268,185,218 shares $111.40 million +2.7%14.6%6.29 $13.61
5/29/20267,973,648 shares $131.09 million -8.1%14.2%7.05 $16.44
5/15/20268,680,186 shares $136.54 million -1.4%15.5%8.19 $15.73
4/30/20268,799,071 shares $114.83 million +8.4%15.7%15.27 $13.05
4/15/20268,114,946 shares $121.32 million -3.3%14.4%10.56 $14.95
3/31/20268,394,357 shares $119.28 million +0.4%14.9%9.32 $14.21
3/13/20268,364,143 shares $112.83 million +3.5%14.9%10.63 $13.49
2/27/20268,080,892 shares $125.25 million +0.8%14.4%8.96 $15.50
2/13/20268,015,222 shares $92.90 million +0.5%14.3%11.67 $11.59
1/30/20267,976,684 shares $95.40 million -5.3%14.2%12 $11.96
1/15/20268,421,475 shares $89.77 million +3.5%15.0%12.18 $10.66
12/31/20258,136,316 shares $84.21 million +19.3%14.5%7.73 $10.35
12/15/20256,821,318 shares $73.81 million -0.8%12.1%5.34 $10.82
11/28/20256,876,864 shares $78.19 million +3.0%12.2%4.09 $11.37
11/14/20256,678,836 shares $57.10 million +2.6%12.0%9.63 $8.55
10/31/20256,509,523 shares $56.37 million -1.8%11.7%6 $8.66
10/15/20256,630,000 shares $57.22 million +8.7%18.0%8.1 $8.63
9/30/20256,100,000 shares $36.17 million -1.3%16.8%9.6 $5.93
9/15/20256,180,000 shares $39.24 million -1.0%17.0%14 $6.35
8/31/20256,240,000 shares $47.05 million +6.7%17.2%16.1 $7.54
8/15/20255,850,000 shares $44.81 million -9.3%16.1%16.6 $7.66
7/31/20256,450,000 shares $50.12 million +9.7%17.8%17.6 $7.77
7/15/20255,880,000 shares $43.81 million -1.8%16.4%15.6 $7.45
6/30/20255,990,000 shares $45.10 million +0.5%16.7%14.1 $7.53
6/15/20255,960,000 shares $51.32 million -3.6%16.6%13.9 $8.61
5/31/20256,180,000 shares $53.52 million +3.2%17.2%13.7 $8.66
5/15/20255,990,000 shares $43.37 million -19.9%16.7%13 $7.24
4/30/20257,480,000 shares $61.93 million -6.4%20.9%16.2 $8.28
4/15/20257,990,000 shares $62.32 million -6.3%22.5%17.3 $7.80
3/31/20258,530,000 shares $64.57 million -1.6%24.1%18.1 $7.57
3/15/20258,670,000 shares $76.21 million +0.1%24.4%17.7 $8.79
2/28/20258,660,000 shares $73.52 million -1.3%24.4%17.4 $8.49
2/15/20258,770,000 shares $83.58 million +0.5%24.6%17.2 $9.53
1/31/20258,730,000 shares $92.19 million -10.7%23.7%15.7 $10.56
1/15/20259,780,000 shares $99.56 million -0.4%26.6%18.4 $10.18
12/31/20249,820,000 shares $119.61 million +1.8%26.7%19 $12.18
12/15/20249,650,000 shares $113.39 million +5.4%26.0%19.5 $11.75
The end may be near for these iconic stocks (Ad)

Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel

Watch Marc Chaikin's free presentation and get his full buy-and-sell list today
11/30/20249,160,000 shares $123.20 million +5.2%24.7%16.8 $13.45
11/15/20248,710,000 shares $120.72 million -3.4%23.5%16.2 $13.86
10/31/20249,020,000 shares $140.26 million -0.4%23.0%17.1 $15.55
10/15/20249,060,000 shares $147.13 million -1.6%23.2%15.7 $16.24
9/30/20249,210,000 shares $154.18 million +9.4%23.6%14.2 $16.74
9/15/20248,420,000 shares $151.14 million +4.6%21.6%11.7 $17.95
8/31/20248,050,000 shares $157.78 million -1.4%20.9%10.2 $19.60
8/15/20248,160,000 shares $137.99 million -2.4%21.2%10.3 $16.91
7/31/20248,360,000 shares $161.77 million +6.0%20.6%10 $19.35
7/15/20247,890,000 shares $130.90 million +0.6%19.4%8 $16.59
6/30/20247,840,000 shares $136.73 million +73.5%19.3%8 $17.44
6/15/20244,520,000 shares $85.34 million +4.2%10.3%5.1 $18.88
5/31/20244,340,000 shares $101.99 million +16.0%11.0%5.5 $23.50
5/15/20243,740,000 shares $99.93 million +58.5%11.9%5 $26.72
4/30/20242,360,000 shares $63.74 million +40.5%10.2%3.3 $27.01
4/15/20241,680,000 shares $27.80 million +16.7%6.4%3.1 $16.55
3/31/20241,440,000 shares $24.54 million +53.9%5.5%3.4 $17.04
3/15/2024935,400 shares $14.90 million +34.8%3.6%2.3 $15.93
2/29/2024694,100 shares $12.82 million -11.5%2.6%1.8 $18.47
2/15/2024783,900 shares $14.45 million -46.7%2.9%2.3 $18.43
1/31/20241,470,000 shares $22.26 million +34.9%5.4%5.1 $15.14
1/15/20241,090,000 shares $11.54 million +3.8%4.0%5.2 $10.59
12/31/20231,050,000 shares $10.70 million -48.5%3.9%5.4 $10.19
12/15/20232,040,000 shares $16.81 million -3.3%7.5%11.1 $8.24
11/30/20232,110,000 shares $17.28 million -2.3%7.8%12.5 $8.19
11/15/20232,160,000 shares $19.16 million +0.5%8.0%13.3 $8.87
10/31/20232,150,000 shares $20.06 million -1.8%7.9%12.9 $9.33
10/15/20232,190,000 shares $19.27 million -0.5%8.1%12.9 $8.80
9/30/20232,200,000 shares $19.91 million +0.9%8.1%12.1 $9.05
9/15/20232,180,000 shares $21.71 million -17.7%8.0%11.5 $9.96
8/31/20232,650,000 shares $27.43 million +33.2%9.8%10.2 $10.35
8/15/20231,990,000 shares $20.32 million +2.6%7.4%6.4 $10.21
7/31/20231,940,000 shares $20.54 million -18.5%8.2%6.1 $10.59
7/15/20232,380,000 shares $27.89 million +15.5%10.1%7.6 $11.72
6/30/20232,060,000 shares $22.17 million -11.6%8.7%6.8 $10.76
6/15/20232,330,000 shares $29.59 million +2.6%9.9%7.6 $12.70
5/31/20232,270,000 shares $23.34 million +0.9%9.6%8.6 $10.28
5/15/20232,250,000 shares $22.37 million +0.5%9.5%10.7 $9.94
4/30/20232,240,000 shares $21.80 million +0.5%9.5%10.7 $9.73
4/15/20232,230,000 shares $22.34 million +0.5%9.5%9.9 $10.02
3/31/20232,220,000 shares $22.71 million +1.8%9.4%10.2 $10.23
3/15/20232,180,000 shares $24.44 million +3.8%7.7%10.5 $11.21
2/28/20232,100,000 shares $23.71 million +1.5%7.0%13.3 $11.29
2/15/20232,070,000 shares $23.91 million +6.7%6.9%13.7 $11.55
1/31/20231,940,000 shares $22.58 million -9.4%6.6%13.7 $11.64
1/15/20232,140,000 shares $23.50 million -1.8%7.2%16.4 $10.98
12/30/20222,180,000 shares $23.00 million No Change7.4%17 $10.55
12/15/20222,180,000 shares $24.96 million No Change7.4%15.9 $11.45
11/30/20222,180,000 shares $27.10 million -5.6%7.4%14.8 $12.43
11/15/20222,310,000 shares $29.48 million -4.9%8.0%14.2 $12.76
The REAL Reason Trump is Invading Iran (Ad)

For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel

Click here to find out what it is.
10/31/20222,430,000 shares $31.93 million -0.4%8.5%15.4 $13.14
10/15/20222,440,000 shares $30.79 million -1.2%8.5%15.7 $12.62
9/30/20222,470,000 shares $31.67 million +14.4%8.6%14.2 $12.82
9/15/20222,160,000 shares $28.21 million -13.6%7.5%10.9 $13.06
8/31/20222,500,000 shares $33.70 million No Change8.8%10.5 $13.48
8/15/20222,500,000 shares $35.40 million +2.9%8.8%8.5 $14.16
7/31/20222,430,000 shares $32.83 million -17.9%9.9%4.1 $13.51
7/15/20222,960,000 shares $43.57 million -1.7%12.1%4.9 $14.72
6/30/20223,010,000 shares $38.59 million -0.7%12.3%5.2 $12.82
6/15/20223,030,000 shares $36.09 million +6.3%12.4%5.2 $11.91
5/31/20222,850,000 shares $30.47 million +4.0%11.7%5.3 $10.69
5/15/20222,740,000 shares $29.10 million +3.8%11.2%5.7 $10.62
4/30/20222,640,000 shares $25.90 million +7.8%11.2%14.4 $9.81
4/15/20222,450,000 shares $27.44 million -3.5%10.4%13.2 $11.20
3/31/20222,540,000 shares $26.59 million -7.3%11.0%13.3 $10.47
3/15/20222,740,000 shares $34.91 million +1.5%12.1%13.2 $12.74
2/28/20222,700,000 shares $38.72 million +5.9%12.0%10.3 $14.34
2/15/20222,550,000 shares $37.69 million -3.4%11.3%9.6 $14.78
1/31/20222,640,000 shares $35.59 million -13.7%12.1%9.9 $13.48
1/15/20223,060,000 shares $41.89 million -1.0%13.4%11.4 $13.69
12/31/20213,090,000 shares $47.68 million +27.2%14.3%10.7 $15.43
12/15/20212,430,000 shares $38.71 million +3.4%11.2%9.4 $15.93
11/30/20212,350,000 shares $42.30 million -0.8%10.9%9.9 $18.00
11/15/20212,370,000 shares $49.68 million -7.8%8.1%9.3 $20.96
10/29/20212,570,000 shares $57.11 million +0.8%8.9%10.3 $22.22
10/15/20212,550,000 shares $63.75 million -1.9%8.8%10.6 $25.00
9/30/20212,600,000 shares $58.68 million +42.9%9.0%11.7 $22.57
9/15/20211,820,000 shares $52.78 million -24.5%6.3%7.6 $29.00
8/31/20212,410,000 shares $68.01 million -11.1%8.4%11.7 $28.22

CGEM Short Interest - Frequently Asked Questions

Short interest is the volume of Cullinan Therapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 10,254,541 shares of CGEM short. 17.43% of Cullinan Therapeutics' shares are currently sold short. Learn More on Cullinan Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CGEM shares currently have a short interest ratio of 19.2. Learn More on Cullinan Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.43% of Cullinan Therapeutics' floating shares are currently sold short.

Cullinan Therapeutics saw a decrease in short interest in July. As of July 31st, there was short interest totaling 10,254,541 shares, a decrease of 0.3% from the previous total of 10,285,963 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

17.43% of Cullinan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biotechnology" compare to Cullinan Therapeutics: Relay Therapeutics, Inc. (19.34%), Celcuity, Inc. (24.28%), Enliven Therapeutics, Inc. (11.47%), Telix Pharmaceuticals Limited (0.08%), Legend Biotech Corporation Sponsored ADR (9.75%), Viking Therapeutics, Inc. (20.41%), Denali Therapeutics Inc. (12.17%), Tango Therapeutics, Inc. (32.98%), Veracyte, Inc. (8.67%), Arcus Biosciences, Inc. (11.15%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.50 billion), Invesco QQQ ($50.36 billion), iShares Russell 2000 ETF ($21.20 billion), Western Digital Corporation ($13.40 billion), SPDR S&P Biotech ETF ($11.59 billion), Nebius Group N.V. ($11.46 billion), iShares 20+ Year Treasury Bond ETF ($7.84 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($7.51 billion), iShares Semiconductor ETF ($6.37 billion), and Financial Select Sector SPDR Fund ($6.34 billion). View all of the most shorted stocks.

Short selling CGEM is an investing strategy that aims to generate trading profit from Cullinan Therapeutics as its price is falling. CGEM shares are trading up $0.25 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cullinan Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CGEM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGEM, twice per month. The most recent reporting period available is July, 31 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CGEM:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

Short interest data for NASDAQ:CGEM is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 8/11/2026. FINRA publishes updated short interest twice a month.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel